Co-Authors
This is a "connection" page, showing publications co-authored by Pierpaolo Di Micco and Corrado Lodigiani.
Connection Strength
3.938
-
Prognostic Value of Fibrinogen among COVID-19 Patients Admitted to an Emergency Department: An Italian Cohort Study. J Clin Med. 2020 Dec 21; 9(12).
Score: 0.920
-
Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate. Medicina (Kaunas). 2020 Sep 27; 56(10).
Score: 0.905
-
Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort. J Clin Med. 2020 May 07; 9(5).
Score: 0.881
-
Compromised Lung Volume and Hemostatic Abnormalities in COVID-19 Pneumonia: Results from an Observational Study on 510 Consecutive Patients. J Clin Med. 2021 Jun 29; 10(13).
Score: 0.238
-
Fondaparinux and bleeding risk in COVID-19: unsolved question. Thromb Res. 2021 04; 200:128-129.
Score: 0.232
-
Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study. Front Med (Lausanne). 2020; 7:569567.
Score: 0.229
-
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. J Cardiovasc Pharmacol. 2020 10; 76(4):369-371.
Score: 0.226
-
Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacol Res. 2020 09; 159:104965.
Score: 0.221
-
Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. J Blood Med. 2021; 12:69-75.
Score: 0.058
-
Differences in the INR evaluation of two different thromboplastins in patients with positivity to lupus anticoagulant in ongoing oral anticoagulation. J Blood Med. 2010; 1:57-60.
Score: 0.028